Bimagrumab + Semaglutide Achieves 17.8 kg Weight Loss While Preserving Muscle in Phase 2 Trial
Bimagrumab 30 mg/kg + semaglutide 2.4 mg achieved -17.8 kg weight loss at 48 weeks vs -3.3 kg placebo, with bimagrumab uniquely targeting fat while preserving or increasing lean mass.
Quick Facts
What This Study Found
Week 48 weight loss: bimagrumab 30 -9.3 kg; semaglutide 2.4 -14.2 kg; combination -17.8 kg; placebo -3.3 kg (all p<0.001 vs placebo). Improvements continued through week 72. Safety consistent with known profiles.
Key Numbers
How They Did This
Double-blind, placebo-controlled phase 2 trial (NCT05616013), 507 adults with obesity randomized 1:1:1:1:1:1:1:1:1 to 9 groups, 48-week treatment + 72-week open-label extension.
Why This Research Matters
The combination addresses GLP-1 therapy's biggest weakness (muscle loss) while enhancing weight loss — potentially the most comprehensive obesity treatment to date.
The Bigger Picture
Combining anabolic (muscle-building) with catabolic (fat-burning) therapies represents a new paradigm in obesity treatment: lose fat while keeping or building muscle.
What This Study Doesn't Tell Us
Phase 2 trial. Lean mass data not detailed in abstract. Nine-arm design means small groups. Long-term effects beyond 72 weeks unknown.
Questions This Raises
- ?How much lean mass was preserved vs semaglutide alone?
- ?Would the combination be cost-effective given two expensive drugs?
- ?Should bimagrumab be added to all GLP-1 therapy for muscle preservation?
Trust & Context
- Key Stat:
- -17.8 kg combination Adding bimagrumab to semaglutide enhanced weight loss beyond either drug alone while targeting fat loss and preserving muscle
- Evidence Grade:
- Phase 2 RCT with multiple treatment arms. Strong efficacy signal with consistent safety. Phase 3 confirmation needed.
- Study Age:
- Published in 2025, NCT05616013.
- Original Title:
- Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
- Published In:
- Nature medicine (2026)
- Authors:
- Heymsfield, Steven B(2), Aronne, Louis J(7), Montgomery, Penelope, Klickstein, Lloyd B, Coleman, Laura A, Dole, Kiran, Mindeholm, Linda, Spruill, Susan, Li, Xingyuan, Attie, Kenneth M
- Database ID:
- RPEP-15292
Evidence Hierarchy
Frequently Asked Questions
What is bimagrumab?
An antibody that blocks activin receptors to prevent muscle breakdown and promote lean mass growth. Combined with semaglutide, it targets fat loss while keeping muscle — addressing the main concern with GLP-1 weight loss drugs.
Is this better than semaglutide alone?
The combination lost 17.8 kg vs 14.2 kg for semaglutide alone and 3.3 kg for placebo. The key advantage is muscle preservation — bimagrumab protects lean mass while semaglutide burns fat.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15292APA
Heymsfield, Steven B; Aronne, Louis J; Montgomery, Penelope; Klickstein, Lloyd B; Coleman, Laura A; Dole, Kiran; Mindeholm, Linda; Spruill, Susan; Li, Xingyuan; Attie, Kenneth M. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.. Nature medicine. https://doi.org/10.1038/s41591-026-04204-0
MLA
Heymsfield, Steven B, et al. "Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.." Nature medicine, 2026. https://doi.org/10.1038/s41591-026-04204-0
RethinkPeptides
RethinkPeptides Research Database. "Bimagrumab plus semaglutide alone or in combination for the ..." RPEP-15292. Retrieved from https://rethinkpeptides.com/research/heymsfield-2026-bimagrumab-plus-semaglutide-alone
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.